Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
https://www.zacks.com/stock/news/2260461/corcept-cort-posts-positive-data-from-cushing-s-syndrome-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260461
Apr 23, 2024 - Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
0
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438
Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
0
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
https://www.zacks.com/stock/news/2259547/will-alkermes-alks-proprietary-drugs-aid-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2259547
Apr 22, 2024 - Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
0
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
https://www.zacks.com/stock/news/2258578/roche-rhhby-alecensa-wins-fda-nod-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2258578
Apr 19, 2024 - Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
0
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
https://www.zacks.com/stock/news/2254638/astrazeneca-s-azn-fasenra-gets-fda-nod-for-asthma-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254638
Apr 12, 2024 - The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
0
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
https://www.zacks.com/stock/news/2253377/lisata-s-lsta-lsta1-gets-fda-orphan-drug-tag-for-osteosarcoma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253377
Apr 10, 2024 - The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.
0
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
https://www.zacks.com/stock/news/2252667/is-it-a-good-idea-to-invest-in-adma-biologics-adma-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252667
Apr 09, 2024 - Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.
0
Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2251479/ligand-pharmaceuticals-lgnd-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2251479
Apr 05, 2024 - Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.
0
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
https://www.zacks.com/stock/news/2251363/candel-cadl-up-on-upbeat-data-from-pancreatic-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251363
Apr 05, 2024 - Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.
0
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
https://www.zacks.com/stock/news/2250719/amarin-amrn-up-7-on-intellectual-property-wins-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250719
Apr 04, 2024 - Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
0
Pages: 12
Page 1